PL3919060T3 - Ekopipam do leczenia zespołu tourette'a - Google Patents

Ekopipam do leczenia zespołu tourette'a

Info

Publication number
PL3919060T3
PL3919060T3 PL21170063.8T PL21170063T PL3919060T3 PL 3919060 T3 PL3919060 T3 PL 3919060T3 PL 21170063 T PL21170063 T PL 21170063T PL 3919060 T3 PL3919060 T3 PL 3919060T3
Authority
PL
Poland
Prior art keywords
ecopipam
treatment
tourettes syndrome
tourettes
syndrome
Prior art date
Application number
PL21170063.8T
Other languages
English (en)
Inventor
Richard E. Chipkin
Rudolf KWAN
Original Assignee
Emalex Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emalex Biosciences, Inc. filed Critical Emalex Biosciences, Inc.
Publication of PL3919060T3 publication Critical patent/PL3919060T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21170063.8T 2012-07-12 2013-07-12 Ekopipam do leczenia zespołu tourette'a PL3919060T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261671044P 2012-07-12 2012-07-12

Publications (1)

Publication Number Publication Date
PL3919060T3 true PL3919060T3 (pl) 2025-10-20

Family

ID=49916578

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21170063.8T PL3919060T3 (pl) 2012-07-12 2013-07-12 Ekopipam do leczenia zespołu tourette'a
PL13815988T PL2872145T3 (pl) 2012-07-12 2013-07-12 Połączone benzazepiny w leczeniu zespołu tourette’a

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13815988T PL2872145T3 (pl) 2012-07-12 2013-07-12 Połączone benzazepiny w leczeniu zespołu tourette’a

Country Status (21)

Country Link
US (2) US11298361B2 (pl)
EP (3) EP3919060B1 (pl)
JP (1) JP6181754B2 (pl)
KR (1) KR20150029713A (pl)
CN (1) CN104540510A (pl)
AU (1) AU2013289922B2 (pl)
CA (1) CA2879020C (pl)
CY (1) CY1125221T1 (pl)
DK (2) DK3919060T3 (pl)
ES (2) ES3041320T3 (pl)
FI (1) FI3919060T3 (pl)
HR (2) HRP20220701T1 (pl)
HU (2) HUE058696T2 (pl)
IL (4) IL300144A (pl)
LT (2) LT2872145T (pl)
PL (2) PL3919060T3 (pl)
PT (2) PT3919060T (pl)
RS (2) RS67203B1 (pl)
SI (2) SI2872145T1 (pl)
SM (2) SMT202200234T1 (pl)
WO (1) WO2014012034A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3057595T1 (sl) 2013-10-18 2020-09-30 Emalex Biosciences, Inc. Spojeni benzazepini za zdravljenje jecljanja
WO2020061410A1 (en) * 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
CN116137811B (zh) * 2020-06-05 2026-01-09 诺埃玛制药公司 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途
US12594281B2 (en) 2024-03-15 2026-04-07 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use
WO2025194153A1 (en) * 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US5302716A (en) 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
US4973586A (en) 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
BE1005064A4 (nl) 1991-07-03 1993-04-06 Asm Fico Tooling Buiginrichting.
GB9127306D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
WO1995025102A1 (en) 1994-03-16 1995-09-21 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
US5607967A (en) 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
IL135659A0 (en) 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
CN1291893A (zh) * 1998-03-02 2001-04-18 先灵公司 D1/d5拮抗剂用于治疗强迫观念与行为失调、体型失调、分离失调、吃喝失调、冲动控制失调与孤独症的用途
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2002354041A1 (en) * 2001-11-06 2003-05-19 John L. Haracz Antimnemonic therapy for hypermemory syndromes
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2012033874A1 (en) 2010-09-10 2012-03-15 Chipkin Richard E Method of treating compulsive self-injurious behaviors
SI3057595T1 (sl) 2013-10-18 2020-09-30 Emalex Biosciences, Inc. Spojeni benzazepini za zdravljenje jecljanja

Also Published As

Publication number Publication date
HRP20251123T1 (hr) 2025-11-21
EP2872145B1 (en) 2022-03-09
HRP20220701T1 (hr) 2022-07-08
FI3919060T3 (fi) 2025-09-15
LT2872145T (lt) 2022-06-27
HUE058696T2 (hu) 2022-09-28
DK2872145T3 (da) 2022-06-13
CY1125221T1 (el) 2025-03-28
CN104540510A (zh) 2015-04-22
PT3919060T (pt) 2025-09-25
SI2872145T1 (sl) 2022-07-29
US20210275540A1 (en) 2021-09-09
LT3919060T (lt) 2025-10-10
PT2872145T (pt) 2022-05-26
IL292725A (en) 2022-07-01
EP4616915A3 (en) 2025-12-17
AU2013289922A1 (en) 2015-01-29
EP2872145A4 (en) 2015-12-02
AU2013289922B2 (en) 2016-12-15
JP2015522082A (ja) 2015-08-03
US11298361B2 (en) 2022-04-12
ES3041320T3 (en) 2025-11-11
SMT202200234T1 (it) 2022-07-21
WO2014012034A1 (en) 2014-01-16
EP2872145A1 (en) 2015-05-20
PL2872145T3 (pl) 2022-06-20
IL300144A (en) 2023-03-01
EP4616915A2 (en) 2025-09-17
IL236403A0 (en) 2015-02-26
ES2914043T3 (es) 2022-06-07
KR20150029713A (ko) 2015-03-18
HK1209336A1 (zh) 2016-04-01
IL284615A (en) 2021-08-31
EP3919060B1 (en) 2025-06-18
US20150164911A1 (en) 2015-06-18
EP2872145B8 (en) 2022-04-13
JP6181754B2 (ja) 2017-08-16
RS67203B1 (sr) 2025-10-31
HUE072922T2 (hu) 2025-12-28
RS63266B1 (sr) 2022-06-30
SI3919060T1 (sl) 2025-11-28
SMT202500353T1 (it) 2025-11-10
DK3919060T3 (da) 2025-09-15
CA2879020A1 (en) 2014-01-16
EP3919060A1 (en) 2021-12-08
CA2879020C (en) 2021-02-09

Similar Documents

Publication Publication Date Title
IL262200A (en) Methods for treating Alport syndrome
ZA201405535B (en) Inhibitors of iap
GB201309274D0 (en) Treatment Of Fuel
LT3919060T (lt) Ekopipamas skirtas tureto sindromo gydymui
GB201207907D0 (en) Treatment of depression
EP2704731A4 (en) TREATMENT OF AVIAN ORIGIN
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201121044D0 (en) Treatment of solutions
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201205449D0 (en) Treatment process
GB201102271D0 (en) Treatment
GB201102269D0 (en) Treatment
GB201102273D0 (en) Treatment
GB201102263D0 (en) Treatment
GB201102265D0 (en) Treatment
GB201102266D0 (en) Treatment
GB201102267D0 (en) Treatment
GB201102270D0 (en) Treatment
GB201102268D0 (en) Treatment
GB201102272D0 (en) Treatment